Special Issue "Molecular and Cellular Targets of Old and New Atypical Antipsychotics"
Deadline for manuscript submissions: 15 May 2021.
Interests: Atypical antipsychotics, G protein-coupled receptors, biased agonism
Interests: Atypical antipsychotics, Stress, Lurasidone
Interests: Atypical antipsychotics, Oxidative stress, Antioxidants
Interests: Atypical antipsychotics, dopamine receptors, allosteric drugs
Interests: Atypical antipsychotics, Schizophrenia, D3 receptor
Interests: Atypical antipsychotics, Drug metabolism, Cytocrome P450
Since the extraordinary discovery in the 70’s of clozapine, still the prototypical atypical antipsychotic, many efforts have been made in order to find better drugs, especially in terms of tolerability and side effects. In fact, unfortunately, the benefits of clozapine compared to the other drugs are somehow overshadow by the risk of severe hematological effects, weight gain and metabolic syndrome.
However, in order to find better drugs, it is imperative to determine the molecular targets that are responsible for atypical antipsychotics efficacy and undesired adverse effects. Despite a large amount of work, the hallmarks defining the ideal antipsychotic are not completely understood and new properties like antioxidant, antistress and neuroprotective have been introduced.
Moreover, besides pharmacodynamics, pharmacokinetics is another key aspect to determine the therapeutic success of atypical antipsychotics in clinical practice, and factors such as inter-individual variability in drug metabolism, drug-drug interactions and patients compliance cannot be underestimated.
With these premises, authors are invited to submit original and review articles to improve our understanding of the pharmacodynamics and pharmacokinetics characteristics of old and new atypical antipsychotics in the Special Issue of Pharmaceuticals “Molecular and cellular targets of old and new atypical antipsychotics”.
Prof. Marco Scarselli
Prof. Marco Riva
Prof. Filippo Caraci
Prof. Roberto Maggio
Prof. Gianmarco Leggio
Prof. Edoardo Spina
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Atypical antipsychotics
- G protein-coupled receptors
- dopamine receptors
- antistress activity
- antioxidant activity
- allosteric drugs
- drug-drug interactions
- drug metabolism
- Antihypertensive Drugs in Pharmaceuticals (17 articles)
- Phytochemicals with actions on the Central Nervous System in Pharmaceuticals (4 articles)
- Neuroactive Compounds in Pharmaceuticals (2 articles)
- CNS-Drugs and Therapy in Pharmaceuticals (4 articles)
- NMDA Receptor Antagonists for Treatment of CNS Disorders in Pharmaceuticals (5 articles)
- Therapeutics Agents for Neural Repair in Pharmaceuticals (7 articles)
- Therapeutic Agents for Neurological Disorders in Pharmaceuticals (11 articles)